Nebenwirkungen · Constella
Constella 290 micrograms hard capsules · Abschnitt 4.8 · PDF-Seite 5
HOS-215727 · Präparat HOS-155512
Description of selected adverse reactions Diarrhoea is the most common adverse reaction and is consistent with the pharmacological action of the active substance. 2% of treated patients experienced severe diarrhoea and 5% of patients discontinued treatment due to diarrhoea in clinical studies. The majority of reported cases of diarrhoea were mild (43%) to moderate (47%); 2% of treated patients experienced severe diarrhoea. Approximately half of the diarrhoea episodes started within the first week of treatment. The diarrhoea resolved within seven days in about one third of patients, however 80 patients (50%) experienced diarrhoea with a duration of more than 28 days (representing 9.9% of all patients treated with linaclotide). Five percent of patients discontinued treatment due to diarrhoea in clinical studies. In those patients in whom diarrhoea led to discontinuation, it resolved after a few days of discontinuing treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-25T17:28:00Z · SHA-256 1b8acfd844e9f1cdcf705e8a60fee70d0baef38df36c3dc76756a130a5ec50d8 · Passage 32b950da8a7a2379c114ba5cb29029a7b87dd9f0778330f6943ddede2d7e7c88 · Zeichen 3484–4422 im Abschnitt